Local event to help black individuals with MS
(WSYR-TV) — Next Friday marks World MS Day, and one local health center is making sure a portion of the population who suffers from MS is getting seen.
Sandra Gibson, a PA-C with MSCS Upstate Comprehensive Care Center, brought along two women dealing with MS, AnnMarie Johnson and Lequanna Brown, to discuss how Central New York can better treat, and diagnose, the African American community.
After a proclamation, May 30th will also be World MS Day here in Syracuse, and it coincides with their event at Syracuse Community Health on South Salina street.
Learn more at Secure.NationalMSSociety.org.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
10 minutes ago
- Hamilton Spectator
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data previously reported- NEWTOWN, Pa., June 12, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona. Dr. Backus' presentation highlighted the importance of treatment adherence as a key requirement for achieving a clinically meaningful improvement in gait disability over 14 weeks of therapy and its sustained therapeutic effect well into 6 months after the end of treatment. The study results confirm controlled and real-world clinical evidence of PoNS Therapy's long-term benefits already reported in people with balance deficit due to traumatic brain injury (TBI). 'The results from this study were received with great interest as they provide the first clinical trial evidence of the long-term therapeutic benefits of PoNS Therapy for functional rehabilitation in the MS population,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We were excited to engage with both US healthcare professionals and Canadian MS specialists and offer additional insights on the body of clinical and mechanistic evidence of PoNS Therapy's effect in MS. We are encouraged by the growing recognition of the importance of PoNS' direct effect on the central nervous system and its targeted mechanism of action as well as how it correlates with a lasting and sustained effect on gait rehabilitation, especially when comparing PoNS Therapy to other interventions limited to peripheral neuromuscular or transcutaneous stimulation.' CMSC attendees were encouraged at Helius' recent successes in obtaining initial reimbursement from federal and private payers and appreciated the Company's relentless effort to engage with health insurance providers, viewing it as a much-needed endeavor to expand access to PoNS Therapy to all people with MS. 'We are excited by the positive conversations had at CMSC regarding both the therapeutic impact of the data presented and the recent announcement of reimbursement from the VA and out of network commercial payers for PoNS,' stated Dane Andreeff, Helius' President and Chief Executive Officer. 'We anticipate that the increase in reimbursement coverage will significantly lower the barrier to prescribe PoNS and allow for greater access to this important therapy.' About PoNS Therapeutic Experience Program (PoNSTEP) The PoNS Therapeutic Experience Program ('PoNSTEP') is a Helius-sponsored, open-label, observational, interventional multi-center outcome research study designed to assess adherence to on-label PoNS Therapy for improvement in gait deficits for patients with multiple sclerosis ('MS') in a real-world clinical setting. The study aims to understand better the relationship between adherence to on label (100-120 minute per day) PoNS Therapy, which combines the PoNS device with physical therapy, and the therapeutic outcome on gait deficit improvement over 14 weeks of study treatment, as measured by changes in the Dynamic Gait Index (DGI) scores. PoNS Therapy is applied in a supervised clinical setting for the first two weeks (Phase 1) and, independently, at home for the remaining 12 weeks (Phase 2). The study also includes a six-month no-treatment follow-up phase aimed at establishing the durability of the therapeutic effect (Phase 3). The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject's adherence to PoNS Therapy. The secondary endpoints are, among others, maintenance of improvement of gait and balance deficit over a 6-month timeframe and clinical global impression of change. The study was performed at six Centers of Excellence across the United States, including Neurology Center of New England in Foxboro (MA), the Shepherd Center in Atlanta (GA), Montefiore Medical Center ('Montefiore') in NY (NY), Oregon Health & Science University ('OHSU') in Portland (OR), MGH Institute of Health Professions in Boston (MA), NYU Langone Health in NY (NY), and recruited 43 MS participants with gait deficit. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
Yahoo
8 hours ago
- Yahoo
Sickle Cell Awareness: Hampton Roads teen siblings diagnosed at birth
NORFOLK, Va. (WAVY) — Sickle Cell Disease is the most common inherited blood disorder in the United States, affecting the lives of 100,000 people, per the Centers for Disease Control and Prevention. Teen siblings, Morgan Tarrer, 15, and Olivia Tarrer, 19, of Virginia Beach represent that number. Data from the CDC also shows approximately 1 in 365 Black or African American newborns are born with SCD, which is the case for Morgan and Olivia, whose parents are carriers. The two were diagnosed at birth and are left with no choice but to embrace their condition as there is still no cure. 'So I have an abnormality of my Hemoglobin,' says Khristina Reid, Virginia Sickle Cell Network founder and mother of Morgan and Olivia. 'So I carry the C-gene, and Olivia and Morgan's dad, he carries the S-gene. Together our children have both genes. The S and C-gene. So they live with Hemoglobin S-C Disease. While there have been many advances in treating sickle cell disease, the reality for the siblings and others is reduced life expectancy and the probability of health complications. 'It's something that I've found is always on your mind,' says Olivia. 'I'm in college. I'm up in New York, so I'm very far from my family. And I've realized, especially living in dorms, being around with friends, that you have to be extra, extra careful. Because with sickle cell, you're very, immunocompromised.' CDC finding reveal, more than 90% of people diagnosed with sickle cell in the US are non-Hispanic black or African American. 'So the reason is, sickle cell disease was the body's kind of defense mechanism against malaria,' says Reid. 'So you will find the highest prevalence of sickle cell disease in your, locations that are near the equator. So Nigeria right now is the, largest country, with the largest population of people living with sickle cell disease.' Those diagnosed with SCD can range in symptoms from frequent infections, anemia, episodes of pain, problems with vision and tiredness. Olivia's says she experiences a great deal of fatigue. While she remains optimistic, there's always concern about her years ahead. 'That has been a problem in school for me,' she says. 'I remember last not last year, but my senior year of high school. All through high school, it was a struggle getting to school because we had it so early. I think the most challenging part is uncertainty about the future. I'm in film. I'm a NYU film, and it's a very physical job. It's also a very, You have to be up early, go to sleep late. And that's when I do that. When I am on set, it's very strenuous, and I worry that I won't be able to be at the same caliber, as my peers.' For information on the Virginia Sickle Cell Network, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
14 hours ago
- Yahoo
Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034)
The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs and emerging BTK inhibitors, which offer targeted, high-efficacy options, especially for progressive forms with limited existing therapies. LAS VEGAS, June 11, 2025 /PRNewswire/ -- Multiple sclerosis is a long-term autoimmune disorder in which the immune system mistakenly attacks the protective sheath surrounding nerves in the brain and spinal cord. This interference disrupts the flow of signals between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision disturbances, and difficulty with mobility. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The therapeutic landscape for multiple sclerosis has undergone a significant transformation, spurred by progress in both drug-based and supportive treatment approaches. Although MS remains without a cure, the market is seeing an expanding array of disease-modifying therapies (DMTs), greater personalization of care, and innovations in how treatments are delivered—all aimed at enhancing patient outcomes and quality of life. Pharmacologically, multiple sclerosis treatment involves both immediate and long-term strategies. For managing acute relapses, high-dose intravenous corticosteroids, most commonly methylprednisolone, continue to be the primary treatment, usually given over 3 to 5 days and followed by a course of tapering oral steroids. Learn more about the multiple sclerosis therapeutics market @ Multiple Sclerosis Drugs Market Intravenous corticosteroids, such as methylprednisolone, are effective for treating acute multiple sclerosis relapses but do not impact the long-term course of the disease. Ongoing disease management relies on disease-modifying therapies (DMTs), selected based on the severity of MS and individual patient requirements, to reduce relapse frequency and delay disability progression. While older injectable multiple sclerosis treatments like PLEGRIDY are still used, newer oral options like MAYZENT, VUMERITY, and MAVENCLAD provide greater convenience and may improve patient adherence. High-efficacy monoclonal antibodies (mAbs), including OCREVUS (now also available in a subcutaneous form), KESIMPTA, and BRIUMVI, are increasingly preferred for home-based therapy. Although LEMTRADA is a potent option, its use is restricted due to safety risks and its inclusion in the REMS program. As key multiple sclerosis drugs such as TYSABRI, TECFIDERA, AUBAGIO, and GILENYA face generic competition, pricing and access are being reshaped. In response, originator companies are shifting focus to next-generation treatments and improved formulations, such as subcutaneous versions and enhanced safety features, to retain market share. Supportive therapies also play a critical role; rehabilitation via exercise and physiotherapy can improve mobility and reduce fatigue, especially in progressive multiple sclerosis. Cognitive behavioral therapy (CBT) and mindfulness strategies help manage mood disorders like depression and anxiety, which in turn support treatment adherence. Additionally, lifestyle modifications involving diet, sleep hygiene, and vitamin D intake aid in symptom control. Assistive devices and occupational therapy further promote independence and enhance quality of life. Find out more on FDA-approved multiple sclerosis medication @ Multiple Sclerosis Treatments Multiple sclerosis treatment lacks neuroprotective and remyelinating therapies, with limited options for progressive multiple sclerosis. Current drugs focus on immune modulation but fail to reverse damage or halt progression. Diagnostic delays remain common due to nonspecific symptoms and limited biomarkers. There is a critical need for early detection tools, personalized therapies, and agents targeting neurodegeneration to improve outcomes in multiple sclerosis. The multiple sclerosis treatment pipeline remains robust, with promising candidates like Remibrutinib, Tolebrutinib, Fenebrutinib, and CNM-Au8 targeting novel mechanisms such as BTK inhibition and neuroprotection. Other multiple sclerosis drugs in the pipeline include Frexalimab (SAR441344) (Sanofi), Vidofludimus calcium (IMU-838) (Immunic Therapeutics), Masitinib (AB Science), PIPE-307 (Contineum Therapeutics), and others. These multiple sclerosis pipeline therapies reflect an increasing emphasis on progressive multiple sclerosis and remyelination to improve long-term outcomes. Discover which therapies are expected to grab major multiple sclerosis market share @ Multiple Sclerosis Treatment Market Tolebrutinib is an oral BTK inhibitor designed to penetrate the blood–brain barrier, targeting both B cells and microglia to mitigate smoldering neuroinflammation in multiple sclerosis (MS). By focusing on central nervous system (CNS) processes that drive neurodegeneration, it aims to address disease progression beyond peripheral inflammation. In March 2025, the US FDA accepted tolebrutinib for priority review as a treatment for non-relapsing secondary progressive multiple sclerosis, to slow relapse-independent disability progression. A decision is anticipated by September 2025, with a parallel evaluation ongoing in the EU. Vidofludimus calcium is an investigational oral therapy currently in Phase III trials for relapsing multiple sclerosis and Phase II for progressive multiple sclerosis. It combines DHODH inhibition for immune regulation with Nurr1 activation for potential neuroprotective effects, aiming to target key mechanisms of neurodegeneration. In April 2025, Immunic reported positive outcomes from the Phase II CALLIPER trial, supporting vidofludimus calcium's role as a Nurr1 activator in progressive multiple sclerosis patients. Fenebrutinib is an innovative, oral, reversible, non-covalent BTK inhibitor in Phase III development for MS. By modulating both adaptive and innate immune responses via B cells and microglia, it offers a dual approach to controlling disease activity and slowing disability. It is currently the only reversible BTK inhibitor in late-stage multiple sclerosis trials. The Phase III program includes FENhance 1 and 2 studies in relapsing multiple sclerosis (vs. teriflunomide) and the FENtrepid trial in primary progressive multiple sclerosis (vs. ocrelizumab), marking the first head-to-head comparison of a BTK inhibitor with an approved PPMS therapy. Regulatory submissions for both RMS and PPMS are planned for 2026. In September 2024, Roche presented 48-week results from the FENopta Phase II open-label extension at the 40th ECTRIMS Congress. Remibrutinib is an oral covalent BTK inhibitor under investigation for multiple sclerosis and chronic spontaneous urticaria (CSU), where it blocks BTK signaling to prevent histamine release. While no Phase I or II trials have yet been conducted for multiple sclerosis, remibrutinib is in Phase III development for CSU through the REMODEL-1 and REMODEL-2 trials. Primary completion is expected in 2026, with regulatory submission anticipated in 2027. Earlier Phase IIb CSU data showed favorable safety and tolerability. CNM-Au8 is an oral gold nanocrystal therapy designed to address mitochondrial dysfunction in multiple sclerosis by boosting NAD+ production, enhancing antioxidant capacity, and activating the heat shock factor-1 pathway to support protein homeostasis. Although the VISIONARY-MS Phase II trial was halted early due to COVID-19, CNM-Au8 is being evaluated in the ongoing Phase II REPAIR-MS trial. Results from REPAIR-MS, along with a planned FDA End-of-Phase II meeting in 2025, will inform the design of a global Phase III trial. In April 2025, Clene Nanomedicine presented promising new data at the AAN Annual Meeting, showing meaningful improvements in cognition and visual function from the VISIONARY-MS open-label extension. Masitinib is being developed for progressive multiple sclerosis with a focus on inhibiting mast cells and microglia, key players in chronic neuroinflammation. This approach aims to slow progression in patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (SPMS). Following positive results from a Phase IIb/III study, a confirmatory Phase III trial is ongoing. In September 2024, AB Science provided an update on masitinib's development at the ECTRIMS 2024 conference. Discover more about the multiple sclerosis pipeline @ Multiple Sclerosis Clinical Trials The anticipated launch of these emerging therapies for multiple sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the multiple sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for Multiple Sclerosis is expected to grow from USD 20 billion in the 7MM in 2024 at a 3.8% CAGR by 2034. This expansion across the 7MM will be driven by the introduction of innovative therapies, remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, and masitinib, among others. Furthermore, multiple sclerosis prevalence is rising due to modifiable environmental and lifestyle factors like Epstein-Barr virus, low vitamin D, smoking, obesity, and night shifts, with genetics and geography also contributing. DelveInsight's latest published market report, titled Multiple Sclerosis – Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the multiple sclerosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The multiple sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases of Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases of Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases of Multiple Sclerosis The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM multiple sclerosis market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this multiple sclerosis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the multiple sclerosis market. Also, stay abreast of the mitigating factors to improve your market position in the multiple sclerosis therapeutic space. Related Reports Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others. Relapsing-Remitting Multiple Sclerosis Market Relapsing-Remitting Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key RRMS companies including Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, among others Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, CinnaGen, Immunic, Mapi Pharma, Apimeds, Genentech (Roche), Merck, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, GlaxoSmithKline, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
